Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
C. Harris
Observed name:
Courtney S. Harris
Institutions:
University of Tsukuba Hospital,
The Christie Hospital,
The Christie NHS Foundation Trust
Observed institutions:
University of Tsukuba Hospital,
The Christie Hospital,
The Christie NHS Foundation Trust
ORCID:
0000-0002-6723-478X
Observed ORCID:
0000-0002-6723-478X
OpenAlex ID:
A5060826690
OA16.02 RAPID-RT: Using Rapid-Learning to Assess the Survival Impact of Limiting Dose to a New Cardiac Avoidance Area During Lung Cancer Radiotherapy
2025
·
C. Faivre-Finn
, C. Morgan
, et al.
·
Journal of Thoracic Oncology
·
1
MA 09.11 Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) – a Feasibility Study
2017
·
K. Haslett
, N. Bayman
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
120: Impact of introducing intensity modulated radiotherapy (IMRT) on curative-intent radiotherapy for lung cancer – a ‘big data’ analysis
2017
·
C. Chan
, D. Woolf
, et al.
·
Lung Cancer
·
1
118: Accelerated hypofractionated intensity modulated radiotherapy (IMRT) for early stage non-small cell lung cancer (NSCLC) in patients not suitable for conventional stereotactic ablative radiotherapy (SABR)
2017
·
V. Lavin
, P. Whitehurst
, et al.
·
Lung Cancer
·
1
The Role of Osteoporosis Agents in Enhancing Spinal Fusion
2025
·
Adrian Lui
, Courtney S. Harris
, et al.
·
Contemporary Spine Surgery
The First Use of Stereotactic Ablative Body Radiotherapy (SABR) in Extra-cranial Non-lung Oligometastatic Disease: A Single Centre
2022
·
S. Bowen Jones
, A. Fatimilehin
, et al.
·
Clinical Oncology
PO-0752: Isotoxic Intensity Modulated Radiotherapy in stage III NSCLC – A feasibility study
2018
·
K. Haslett
, L. Ashcroft
, et al.
·
Radiotherapy and Oncology
PDF
PO-0753: Phase I trial evaluating MEK inhibitor selumetinib with concomitant thoracic radiotherapy in NSCLC
2018
·
K. Haslett
, F. Blackhall
, et al.
·
Radiotherapy and Oncology
PDF
Phase I trial evaluating MEK inhibitor selumetinib with concomitant thoracic radiotherapy in non-small-cell lung cancer
2018
·
K. Haslett
, F. Blackhall
, et al.
·
Lung Cancer
Isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC) – a feasibility study
2018
·
K. Haslett
, L. Ashcroft
, et al.
·
Lung Cancer
MA 17.14 Phase I Trial Evaluating MEK Inhibitor Selumetinib with Concomitant Thoracic Radiotherapy in Non-Small-Cell Lung Cancer
2017
·
K. Haslett
, F. Blackhall
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
11
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type